Literature DB >> 3920702

Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients--relationship to drug concentrations.

G Alfredsson, C Härnryd, F A Wiesel.   

Abstract

Schizophrenic patients were treated with fixed doses of sulpiride (800 mg/day) or chlorpromazine (CPZ) (400 mg/day) during a period of 8 weeks using a double-blind design. There were 25 patients in each group and all of them fulfilled the Research Diagnostic Criteria (RDC) for schizophrenia. Autistic and psychotic symptoms were rated with subscales developed from the Comprehensive Psychopathological Rating Scale (CPRS). Autistic symptoms were also rated with a subscale of the Nurse's Observation Scale for Inpatient Evaluation (NOSIE). Sulpiride was superior to CPZ in reducing the autistic symptoms. Patients with low concentrations of sulpiride in serum had a better recovery rate from autistic symptoms than those with high concentrations. Both drugs reduced positive psychotic symptoms to the same degree.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3920702     DOI: 10.1007/bf00427315

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial.

Authors:  G B Cassano; P Castrogiovanni; L Conti; L Bonollo
Journal:  Curr Ther Res Clin Exp       Date:  1975-02

2.  A comprehensive psychopathological rating scale.

Authors:  M Asberg; S A Montgomery; C Perris; D Schalling; G Sedvall
Journal:  Acta Psychiatr Scand Suppl       Date:  1978

3.  [Clinical-neuroleptic investigation of N-((1-ethyl-pyrrolidine-2-yl)-methyl)-2-methoxy-5-sulfamyl-benzamide-neuroleptic sulpiride (Dogmatil) in acutly ill schizophrenics].

Authors:  H J Haase; L Floru; F Ulrich
Journal:  Int Pharmacopsychiatry       Date:  1974

Review 4.  The substituted benzamides--a novel class of dopamine antagonists.

Authors:  P Jenner; C D Marsden
Journal:  Life Sci       Date:  1979-08-06       Impact factor: 5.037

5.  Controlled trial of sulpiride in chronic schizophrenic patients.

Authors:  J G Edwards; J R Alexander; M S Alexander; A Gordon; T Zutchi
Journal:  Br J Psychiatry       Date:  1980-12       Impact factor: 9.319

6.  A mass fragmentographic method for the determination of chlorpromazine and two of its active metabolites in human plasma and CSF.

Authors:  G Alfredsson; B Wode-Helgodt; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1976-07-28       Impact factor: 4.530

7.  Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients--relationship to drug concentrations.

Authors:  G Alfredsson; C Härnryd; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine.

Authors:  B Wode-Helgodt; S Borg; B Fyrö; G Sedvall
Journal:  Acta Psychiatr Scand       Date:  1978-08       Impact factor: 6.392

9.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

10.  Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients.

Authors:  C Härnryd; L Bjerkenstedt; B Gullberg; G Oxenstierna; G Sedvall; F A Wiesel
Journal:  Acta Psychiatr Scand Suppl       Date:  1984
View more
  7 in total

1.  Sulpiride addition in a case of fluvoxamine-refractory obsessive-compulsive disorder without comorbid psychopathology.

Authors:  L Sevincok; A Uslu; H Kaynak; F Dereboy
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Use of sulpiride in a case of atypical autism.

Authors:  D W Scott; P Eames
Journal:  J Autism Dev Disord       Date:  1988-03

Review 3.  A risk-benefit assessment of sulpiride in the treatment of schizophrenia.

Authors:  M C Mauri; S Bravin; A Bitetto; R Rudelli; G Invernizzi
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 4.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

5.  An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.

Authors:  F A Wiesel; A L Nordström; L Farde; B Eriksson
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

6.  A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites.

Authors:  B M Cohen; J F Lipinski; C Waternaux
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography.

Authors:  G Wik; F A Wiesel; I Sjögren; G Blomqvist; T Greitz; S Stone-Elander
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.